CDTRP 2024 Research Innovation Grant Competition Results
CDTRP is thrilled to announce the results of the CDTRP 2024 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.
We would like to extend our warmest congratulations to Dr. Caroline Lamarche and her team for being awarded the CDTRP UdeM Research Innovation Grant. We wish them all the best as they embark on their innovative project!
The Transplantation Program of the Université de Montréal would like to congratulate Dr. Caroline Lamarche on winning the CDTRP innovation grant in the 2024 competition for her project entitled “Tacrolimus-resistant regulatory T cells for adoptive immunotherapy”. The Transplantation Program of the Université de Montréal is proud to contribute to the CDTRP grant competitions and thus participate in transplantation and organ donation research in Canada.
The 2 projects funded by a CDTRP Université de Montréal grant illustrate the mission of the Transplantation Program of the Université de Montréal, which is to support innovation in research and clinical practice in order to improve the care of transplanted donors, families and patients.
-Transplantation Program of the Université de Montréal
CDTRP UdeM Research Innovation Grant : Dr. Caroline Lamarche
Project Title: Tacrolimus-resistant regulatory T cells for adoptive immunotherapy
Main affiliation: Université de Montréal
Theme: 4 – Tailor an Optimal Immune System for Each Patient
Lay Abstract
Transplantation save lives. However, patients need to take anti-rejection drugs. Those drugs come with many side effects. For example, they increase the risk of cardiovascular diseases, infection and cancer. In the last decade, an alternative to those anti-rejection drugs has emerge. It is the injection of regulatory T cells (Tregs), the good cells of the immune system. We collect white blood cells (immune cells) from a transplant recipient. Then, we isolate the good guys (Tregs) and grow them in a laboratory. Finally, the cells are re-infused to the same patient. This was shown to be safe and doable. It allows to decrease the number of anti-rejection drugs. However, most patients still need to take tacrolimus, one of the anti-regection drug. Unfortunately, this drug also affect the good cells (Tregs) we injected. Our goal here is to modify Tregs to make them resistant to tacrolimus. Our study will have to main aims.
First, we will study in detail the impact of tacrolimus on Tregs, the good cells. Then, we will modify the Tregs genetically, making them tacrolimus-resistant. We will show that it is possible and study the impact on the cells. The ultimate goal would be to develop this technique and bring it to a clinical trial. If Tregs are resistant to tacrolimus, it could make them more effective. Indeed, they might survive longer or grow more in patients after injection.